(4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosahexaenoic acid

Metabolite details

Identifier

SEVOKGDVLLIUMT-SKSHMZPZSA-N

InChI Key

SEVOKGDVLLIUMT-SKSHMZPZSA-N

IUPAC name

(4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoic acid

Preferred name

(4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosahexaenoic acid

INN name

—

Synonym

13-hydroxy-4Z,7Z,10Z,14E,16Z,19Z-docosahexaenoic acid

ChEBI

CHEBI:72608

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Collagen induced arthritis in dba/1j mice associates with oxylipin changes in plasma
• Efficacy of Zhuyu Pill Intervention in a Cholestasis Rat Model: Mutual Effects on Fecal Metabolism and Microbial Diversity
• Lipid mediators of inflammation in BALF 3-19 days after infection with influenza.
• Lipid mediators of inflammation in BALF 6-19 days after infection with influenza.
• Lipid mediators of inflammation in BALF 3-11 days after infection with influenza.
• Lipid mediators of inflammation in BALF 3-13 days after infection with influenza.
• Diallyl disulfide (DADS) ameliorates intestinal Candida albicans infection by modulating the gut microbiota and metabolites and providing intestinal protection in mice
• Alterations in the gut microbiota and metabolomics of seafarers after a six-month sea voyage

Observed in differential profiles

• Control_vs_CIA
• Control_vs_CF_high
• Mock_18_days_vs_X31_19_days
• Mock_19d_vs_PR8_19d
• G1_Mock_11_day_vs_G5_PR8_11_day
• Mock_13d_vs_PR8_13d
• G1_PBS_vs_G2_DSS
• Control_0d_vs_Treatment_180d